drugset / Trial / NCT01609218

A Study of LY2140023 in Healthy Participants

NCT01609218

Phase 1 Completed 27 enrolled Denovo Biopharma LLC
RandomizedCrossoverOpen-labelOther

Summary

The study will evaluate the effect of activated charcoal on absorption of LY2140023. The study involves a single dose of 80 milligrams (mg) LY2140023 taken as 1 tablet by mouth 2 times during study (once with activated charcoal, once without activated charcoal). This study will last approximately 16 days, not including screening. Screening is required within 28 days prior to study entry.

Timeline

Start
2012-06
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Activated Charcoal Other / unclassified 75 g Oral
Subject LY2140023 Unknown 80 mg Oral

Indications

No indication recorded.